FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: Priceline.com, Citigroup, Transocean and More
- Lightning Round OT: STEC, ICICI Bank and More
- Herbalife Vs. Hedge Funds
- Cramer Jeers J&J, Applauds Abbott
- Cramer: In This Relay-Race Market, Who Gets Baton Next?
- Cramer's Trade on Status-Conscious Consumers
- Mad Mail: Buy the Berkshire Hathaway Split?
- Lightning Round: American Express, McDonald's, Frontline and More
- Lightning Round OT: Ciena, Kinder Morgan Energy and More
- Don’t Pay Up for This Trade-Down Retailer
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
A recession almost always means pinching pennies, tightening the belt and cutting back on frivolous expenses as a way to save money. So you’d think that Botox, breast implants and stomach bands would be the first things to go when the market tanks. But Allergan’s [AGN
Loading...
()
] fourth-quarter report told a different story, with the company beating Wall Street expectations by 3 cents a share. So it’s obvious the desire for wrinkle-free skin, and other totally narcissistic physical enhancements, hasn’t left us yet.
But Allergan is much more than just cosmetics, which account for only 30% of sales. Medical products are what drive this company’s business. In 2008, the eye-care pharmaceuticals division alone, with its treatments for glaucoma, inflammation and dry-eyes, pulled in 46% of total revenues. And CEO David Pyott told Cramer on Wednesday that Allergan has six other products under review with the Food and Drug Administration. With that kind of diversity, it doesn’t look like a downturn would cripple this company.
Cramer spoke at length with Pyott, discussing new product releases, competition with Johnson & Johnson [JNJ
Loading...
()
] and Medicis Pharma [MRX
Loading...
()
], even $50 Botox coupons. Allergan, which looks like “Pfizer [PFE
Loading...
()
] with growth,” tells a “complicated story,” the Mad Money host said. He likes the exposure to usually recession-proof health care, but the economy could still drag heavily on business.
So what did Cramer decide? Is AGN a buy? Watch the video to find out.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes